Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Non-Current Debt (2025)

CG Oncology's Non-Current Debt history spans 1 years, with the latest figure at $3.0 million for Q4 2025.

  • For Q4 2025, Non-Current Debt changed N/A year-over-year to $3.0 million; the TTM value through Dec 2025 reached $3.0 million, changed N/A, while the annual FY2025 figure was $3.0 million, N/A changed from the prior year.
  • Non-Current Debt reached $3.0 million in Q4 2025 per CGON's latest filing, roughly flat from $3.0 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $3.0 million in Q3 2025 to a low of $3.0 million in Q3 2025.